Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
XYREM (sodium oxybate) is an oral solution small molecule approved in 2002 for narcolepsy, a chronic neurological disorder characterized by excessive daytime sleepiness and cataplexy. The drug works as a CNS depressant that promotes restorative sleep and reduces daytime symptom severity. It is a long-established, highly specialized therapeutic addressing a rare but significant patient population.
Product is at commercial peak with stable reimbursement; team focus is on maximizing existing patient base and defending market position as LOE approaches.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy
Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy
Sodium Oxybate in Patients With Chronic Fatigue Syndrome.
Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia
Worked on XYREM at Jazz Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moXYREM represents a peak-lifecycle opportunity in a specialized, high-touch indication with a defined patient base and stable commercial performance. Professionals joining this product should expect focused defensive strategy work, patient retention initiatives, and preparation for LOE management rather than launch-phase growth activities.